Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven

Recombinant factor VIIa (rFVIIa) (NovoSeveng) is used to treat bleeding episodes in hemophilia A and B patients with inhibitor antibodies against factor VIII (FVIII) and factor IX. rFVIIIa has been studied in home treatment of mild-to-moderate joint, muscle, and mucocutaneous bleeds to assess safety...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood coagulation & fibrinolysis 2000-04, Vol.11 (3), p.239-242
Hauptverfasser:	JOHANNESSEN, M, ANDREASEN, R. B, NORDFANG, O
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Factor IX - metabolism Factor VII - administration & dosage Factor VIIa Factor VIII - metabolism Hemophilia A - blood Hemophilia A - drug therapy Hemophilia B - blood Hemophilia B - drug therapy Humans Medical sciences Pharmacology. Drug treatments Recombinant Proteins - administration & dosage Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!